AVBP
ArriVent BioPharma, Inc.
Next earnings Aug 10, 2026 · consensus $-1.01 EPS
Last earnings -5.5% on 2026-05-11
$34.00
▲ +0.52%$34.00▲ +48.41%
over 1Y
L $16.95EODHDH $34.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.5%
1W+0.5%
1M+23.8%
3M+58.7%
YTD+63.5%
1Y+48.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.08x).
Return on equity -54.1% · latest
ArriVent BioPharma, Inc. shows limited reported revenue, and -54.1% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$74.6M | -$94.3M | -$178M |
| Net income | -$69.3M | -$80.5M | -$166M |
| Diluted EPS | -$32.38 | -$2.56 | -$4.32 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.46B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-11.1%
FCF yield—
Quality & risk
ROIC (est.)-45.7%
Free cash flow—
Total debt—
Net cash$45.5M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+29.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-05-112026-05-11open ↗424B5Filing2026-05-11open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗SCHEDULE 13G/AFiling2026-05-06open ↗ARSPeriod ending 2025-12-312026-04-28open ↗DEFA14AFiling2026-04-28open ↗
Frequently asked
- Is ArriVent BioPharma, Inc. (AVBP) a buy?
- AVBP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.08x).
- What is ArriVent BioPharma, Inc.'s quality score?
- AVBP scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001868279, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 6:18:13 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.